A retrospective real-world study of early short-course remdesivir in non-hospitalized COVID-19 patients at high risk for progression: low rate of hospitalization or death, regardless of immunocompetence status

Introduction: The evidence for remdesivir therapy in immunocompromised patients is scarce. To evaluate remdesivir (RDV) effectiveness and safety in COVID-19 outpatients at high risk for progression in a real-world setting, we compare the outcome in immunocompromised (IC) patients with that in non-im...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos-Rincón, José Manuel, Pinargote-Celorio, Héctor, Llenas-García, Jara, Moreno-Pérez, Oscar, González-Cuello, Inmaculada, Gonzalez-de-la-Aleja, Pilar, Martínez-López, Belén, Reus, Sergio, García-López, María, Rodríguez, Juan Carlos, Boix, Vicente, Merino, Esperanza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597661/
https://www.ncbi.nlm.nih.gov/pubmed/37881188
http://dx.doi.org/10.3389/fphar.2023.1218650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597661/
https://www.ncbi.nlm.nih.gov/pubmed/37881188
http://dx.doi.org/10.3389/fphar.2023.1218650

Ejemplares similares